Thus, SDC1 is an appropriate ligand for developing a targeting LB-MSN nanoparticle drug delivery system for improving targeted therapy of stromal abundant pancreatic cancer through SDC1/IGF1R receptor-mediated endocytosis. This evidence concerns the gene SDC1 and pancreatic neoplasm.